Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ – Get Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 34,933 shares, an increase of 81.8% from the June 15th total of 19,219 shares. Based on an average trading volume of 35,762 shares, the short-interest ratio is presently 1.0 days. Approximately 1.6% of the company’s shares are short sold.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Independent Advisor Alliance purchased a new position in shares of Invesco Nasdaq Biotechnology ETF in the 4th quarter valued at $653,000. WMS Group LLC acquired a new position in shares of Invesco Nasdaq Biotechnology ETF during the 4th quarter valued at $4,255,000. Ignite Planners LLC purchased a new stake in Invesco Nasdaq Biotechnology ETF during the 4th quarter worth $220,000. International Assets Investment Management LLC purchased a new stake in Invesco Nasdaq Biotechnology ETF during the 4th quarter worth $41,000. Finally, Royal Bank of Canada purchased a new stake in Invesco Nasdaq Biotechnology ETF during the 4th quarter worth $37,000.
Invesco Nasdaq Biotechnology ETF Trading Up 0.1%
NASDAQ:IBBQ traded up $0.03 on Friday, hitting $32.62. 14,223 shares of the stock were exchanged, compared to its average volume of 29,863. The stock has a fifty day moving average of $30.70 and a 200-day moving average of $29.71. The stock has a market cap of $73.72 million, a PE ratio of 17.03 and a beta of 0.60. Invesco Nasdaq Biotechnology ETF has a fifty-two week low of $21.87 and a fifty-two week high of $34.22.
Invesco Nasdaq Biotechnology ETF Announces Dividend
Invesco Nasdaq Biotechnology ETF Company Profile
The Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index, a modified market-cap-weighted index of US biotechnology and pharmaceutical companies listed on the NASDAQ. IBBQ was launched on Jun 11, 2021 and is managed by Invesco.
Featured Stories
- Five stocks we like better than Invesco Nasdaq Biotechnology ETF
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Invesco Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
